The American journal of medicine
-
Primary clinicians foster long-term relationships with patients and play key roles in the treatment journey for patients with cancer. Primary clinicians are important members of the multidisciplinary team and are central in coordinating and providing supportive care. The use of immune checkpoint inhibitors in adjuvant/neoadjuvant treatments and metastatic disease requires an awareness of their long-term survival benefits and immune-related adverse events (irAEs). ⋯ Delayed irAEs underscore the importance of continued clinical vigilance following treatment, as primary clinicians are patients' most enduring point of contact. Primary clinicians have a critical role in supporting the care of patients with cancer and ensuring appropriate irAE recognition, monitoring, and intervention. Long-term continuity of care is critical for the immuno-oncology patient journey.
-
An increased understanding of the predisposing genetics and complex pathogenic mechanisms of Alzheimer's disease have facilitated delineation of the long preclinical course and re-invigorated the search for disease-modifying treatments. Establishment of accurate blood-based biomarkers has enabled preclinical identification of early disease and permits trials of preventative treatment and quantitative monitoring of therapeutic effects. The broad range of therapeutic possibilities encompasses gene editing, enzyme activators and inhibitors, antisense oligonucleotides, and antagonists of receptors for inflammatory mediators.